Lipid-lowering - Translating evidence into benefits

Atherosclerosis Supplements

Volumn 2, Issue 4, 2002, Pages 1-3

  Shepherd, James ^a   Barter, Philip ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE;

CORONARY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS;

EID: 0036549210     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00015-0     Document Type: Conference Paper

References (14)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Verschuren W.M., Jacobs D.R., Bloemberg B.P., Kromhout D., Menotti A., Aravanis C., Blackburn H., Buzina R., Dontas A.S., Fidanza F., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. J. Am. Med. Assoc. 274:1995;131-136.
3. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 27:1998;1615-1622.
4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: National Cholesterol Education Program. Summary of the Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015-23.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
6. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyrola K, for the Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
7. McBride P., Schrott H.G., Plane M.B., Underbakke G., Brown R.L. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch. Intern. Med. 158:1998;1238-1244.
8. Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160:2000;459-467.
9. EUROASPIRE Study Group. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18:1569-82.
10. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
11. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 87:((Suppl)):2001;28B-32B.
12. Davidson M., Ma P., Stein E., Gotto A.M., Raza A., Chitra R., Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin vs. atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89:2002;268-275.
13. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomised, double-blind study. J. Cardiovasc. Risk. 8:2001;383-390.
14. Stein E, Strutt KL, Miller E, Southworth H. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001;37(Suppl A):292A. Abstract 1261-176.